Literature DB >> 29221463

Correction to: Recessive VARS2 mutation underlies a novel syndrome with epilepsy, mental retardation, short stature, growth hormone deficiency, and hypogonadism.

Abdulaziz Alsemari1,2, Banan Al-Younes3,2, Ewa Goljan3,2, Dyala Jaroudi3,2, Faisal BinHumaid3,2, Brian F Meyer3,2, Stefan T Arold4, Dorota Monies5,6.   

Abstract

CORRECTION: After publication of the article [1], it has been brought to our attention that there is a nomenclature issue with this article. At the time of acceptance, the VARS2 mutation was considered equivalent to the VARS2 mutation. However, this has changed so that VARS now only refers to shorter mitochondrial sequence of valyl-tRNA synthesase containing 1093 amino acids. "Therefore, in the context of this article, every usage of "VARS2" should be replaced with "VARS" when referring to the causative variant".

Entities:  

Year:  2017        PMID: 29221463      PMCID: PMC5723066          DOI: 10.1186/s40246-017-0130-6

Source DB:  PubMed          Journal:  Hum Genomics        ISSN: 1473-9542            Impact factor:   4.639


Correction

After publication of the article [1], it has been brought to our attention that there is a nomenclature issue with this article. At the time of acceptance, the VARS2 mutation was considered equivalent to the VARS mutation. However, this has changed so that VARS2 now only refers to shorter mitochondrial sequence of valyl-tRNA synthesase containing 1093 amino acids. Therefore, in the context of this article, every usage of “VARS2” should be replaced with “VARS” when referring to the causative variant.
  1 in total

1.  Recessive VARS2 mutation underlies a novel syndrome with epilepsy, mental retardation, short stature, growth hormone deficiency, and hypogonadism.

Authors:  Abdulaziz Alsemari; Banan Al-Younes; Ewa Goljan; Dyala Jaroudi; Faisal BinHumaid; Brian F Meyer; Stefan T Arold; Dorota Monies
Journal:  Hum Genomics       Date:  2017-11-14       Impact factor: 4.639

  1 in total
  1 in total

1.  A novel VARS2 gene variant in a patient with epileptic encephalopathy.

Authors:  Lucija Ruzman; Ivana Kolic; Jelena Radic Nisevic; Antonija Ruzic Barsic; Ingrid Skarpa Prpic; Igor Prpic
Journal:  Ups J Med Sci       Date:  2019-10-18       Impact factor: 2.384

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.